FDA approves Simtriyo for treating ADHD in children and adults

The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.

source https://medicalxpress.com/news/2026-07-fda-simtriyo-adhd-children-adults.html

Comments